Literature DB >> 23221426

Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells.

Nadejda Beliakova-Bethell1, Jin X Zhang, Akul Singhania, Vivian Lee, Valeri H Terry, Douglas D Richman, Celsa A Spina, Christopher H Woelk.   

Abstract

OBJECTIVE: To assess the off-target effects of the histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA) in human primary CD4 T cells.
DESIGN: A pharmacologically relevant concentration (340 nmol/l) of SAHA was shown to significantly increase histone hyperacetylation by 24 h and this length of treatment was selected to determine its impact on gene expression in primary CD4 T cells.
METHODS: Illumina Beadchips for microarray gene expression analysis were used to analyze differential gene expression between cells treated or not with SAHA with a paired analysis using multivariate permutation tests. Gene ontology, biological pathway and protein interaction network analyses were used to identify the higher order biological processes affected by SAHA treatment.
RESULTS: Modest modulation by SAHA was observed for 1847 genes with 80% confidence level of no more than 10% false positives. A thousand genes were upregulated by SAHA and 847 downregulated. Pathways and gene ontologies overrepresented in the list of differentially expressed genes included Glycolysis/Gluconeogenesis, tRNA Modification, and the Histone Acetyltransferase Complex. Protein interaction network analysis revealed that transcription factor c-Myc, which was downregulated by SAHA treatment at the mRNA level, interacts with a number of SAHA-responsive genes.
CONCLUSIONS: The effects on transcription by SAHA were sufficiently modest to support trials to activate HIV replication as part of an eradication strategy. SAHA did not appear to modulate proliferative or apoptotic processes to a great extent, which might impact the ability of patients to eradicate the virus reservoir following activation by HDACi treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23221426      PMCID: PMC3752851          DOI: 10.1097/QAD.0b013e32835b3e26

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  45 in total

1.  Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3.

Authors:  A L Gartel; X Ye; E Goufman; P Shianov; N Hay; F Najmabadi; A L Tyner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  MYC recruits the TIP60 histone acetyltransferase complex to chromatin.

Authors:  Scott R Frank; Tiziana Parisi; Stefan Taubert; Paula Fernandez; Miriam Fuchs; Ho-Man Chan; David M Livingston; Bruno Amati
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

3.  BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Authors:  Camellia Banerjee; Nancie Archin; Daniel Michaels; Anna C Belkina; Gerald V Denis; James Bradner; Paola Sebastiani; David M Margolis; Monty Montano
Journal:  J Leukoc Biol       Date:  2012-07-16       Impact factor: 4.962

Review 4.  Prospects: histone deacetylase inhibitors.

Authors:  Milos Dokmanovic; Paul A Marks
Journal:  J Cell Biochem       Date:  2005-10-01       Impact factor: 4.429

5.  Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.

Authors:  Bhupinder S Mann; John R Johnson; Kun He; Rajeshwari Sridhara; Sophia Abraham; Brian P Booth; Leigh Verbois; David E Morse; Josephine M Jee; Sarah Pope; Ravi S Harapanhalli; Ramzi Dagher; Ann Farrell; Robert Justice; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

6.  A novel transrepression pathway of c-Myc. Recruitment of a transcriptional corepressor complex to c-Myc by MM-1, a c-Myc-binding protein.

Authors:  A Satou; T Taira; S M Iguchi-Ariga; H Ariga
Journal:  J Biol Chem       Date:  2001-10-03       Impact factor: 5.157

7.  Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.

Authors:  Nancie M Archin; Kara S Keedy; Amy Espeseth; Herbert Dang; Daria J Hazuda; David M Margolis
Journal:  AIDS       Date:  2009-09-10       Impact factor: 4.177

Review 8.  Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.

Authors:  Laurence Colin; Carine Van Lint
Journal:  Retrovirology       Date:  2009-12-04       Impact factor: 4.602

Review 9.  Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

10.  Glucose metabolism as a target of histone deacetylase inhibitors.

Authors:  Suzanne E Wardell; Olga R Ilkayeva; Heather L Wieman; Daniel E Frigo; Jeffrey C Rathmell; Christopher B Newgard; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2008-12-23
View more
  18 in total

1.  Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.

Authors:  Nancie M Archin; Jennifer L Kirchherr; Julia Am Sung; Genevieve Clutton; Katherine Sholtis; Yinyan Xu; Brigitte Allard; Erin Stuelke; Angela D Kashuba; Joann D Kuruc; Joseph Eron; Cynthia L Gay; Nilu Goonetilleke; David M Margolis
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

2.  Reactivation of latent HIV: do all roads go through P-TEFb?

Authors:  Sona Budhiraja; Andrew P Rice
Journal:  Future Virol       Date:  2013-07-01       Impact factor: 1.831

3.  Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.

Authors:  Nadejda Beliakova-Bethell; Amey Mukim; Cory H White; Savitha Deshmukh; Hosiana Abewe; Douglas D Richman; Celsa A Spina
Journal:  J Biol Chem       Date:  2019-02-11       Impact factor: 5.157

4.  HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

Authors:  Nancy M Archin; Rosalie Bateson; Manoj K Tripathy; Amanda M Crooks; Kuo-Hsiung Yang; Noelle P Dahl; Mary F Kearney; Elizabeth M Anderson; John M Coffin; Matthew C Strain; Douglas D Richman; Kevin R Robertson; Angela D Kashuba; Ronald J Bosch; Daria J Hazuda; Joann D Kuruc; Joseph J Eron; David M Margolis
Journal:  J Infect Dis       Date:  2014-03-11       Impact factor: 5.226

5.  Evaluation of the Innate Immune Modulator Acitretin as a Strategy To Clear the HIV Reservoir.

Authors:  Edurne Garcia-Vidal; Marc Castellví; Maria Pujantell; Roger Badia; Antoni Jou; Lucia Gomez; Teresa Puig; Bonaventura Clotet; Ester Ballana; Eva Riveira-Muñoz; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

6.  Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells.

Authors:  Brian Reardon; Nadejda Beliakova-Bethell; Celsa A Spina; Akul Singhania; David M Margolis; Douglas R Richman; Christopher H Woelk
Journal:  AIDS       Date:  2015-11       Impact factor: 4.177

7.  Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency.

Authors:  Cory H White; Harvey E Johnston; Bastiaan Moesker; Antigoni Manousopoulou; David M Margolis; Douglas D Richman; Celsa A Spina; Spiros D Garbis; Christopher H Woelk; Nadejda Beliakova-Bethell
Journal:  Antiviral Res       Date:  2015-09-04       Impact factor: 5.970

8.  Use of GapmeRs for gene expression knockdowns in human primary resting CD4+ T cells.

Authors:  Hosiana Abewe; Savitha Deshmukh; Amey Mukim; Nadejda Beliakova-Bethell
Journal:  J Immunol Methods       Date:  2019-10-17       Impact factor: 2.303

9.  Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.

Authors:  Thomas Aagaard Rasmussen; Ole Schmeltz Søgaard; Christel Brinkmann; Fiona Wightman; Sharon R Lewin; Jesper Melchjorsen; Charles Dinarello; Lars Østergaard; Martin Tolstrup
Journal:  Hum Vaccin Immunother       Date:  2013-01-31       Impact factor: 3.452

10.  Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

Authors:  Datsen George Wei; Vicki Chiang; Elizabeth Fyne; Mini Balakrishnan; Tiffany Barnes; Michael Graupe; Joseph Hesselgesser; Alivelu Irrinki; Jeffrey P Murry; George Stepan; Kirsten M Stray; Angela Tsai; Helen Yu; Jonathan Spindler; Mary Kearney; Celsa A Spina; Deborah McMahon; Jacob Lalezari; Derek Sloan; John Mellors; Romas Geleziunas; Tomas Cihlar
Journal:  PLoS Pathog       Date:  2014-04-10       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.